These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26981945)

  • 1. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Pfeffer MA; Claggett B; Probstfield JL
    N Engl J Med; 2016 Mar; 374(11):1095-6. PubMed ID: 26981945
    [No Abstract]   [Full Text] [Related]  

  • 2. [Not Available].
    Wachter J
    MMW Fortschr Med; 2024 Jun; 166(10):11. PubMed ID: 38806898
    [No Abstract]   [Full Text] [Related]  

  • 3. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Derosa G; Maffioli P
    N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
    [No Abstract]   [Full Text] [Related]  

  • 4. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Tsutsumi Y; Tsujimoto Y; Ikenoue T
    N Engl J Med; 2016 Mar; 374(11):1094-5. PubMed ID: 26981946
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
    Holman RR; Bethel MA; George J; Sourij H; Doran Z; Keenan J; Khurmi NS; Mentz RJ; Oulhaj A; Buse JB; Chan JC; Iqbal N; Kundu S; Maggioni AP; Marso SP; Öhman P; Pencina MJ; Poulter N; Porter LE; Ramachandran A; Zinman B; Hernandez AF
    Am Heart J; 2016 Apr; 174():103-10. PubMed ID: 26995376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance.
    Reiner DJ; Mietlicki-Baase EG; McGrath LE; Zimmer DJ; Bence KK; Sousa GL; Konanur VR; Krawczyk J; Burk DH; Kanoski SE; Hermann GE; Rogers RC; Hayes MR
    J Neurosci; 2016 Mar; 36(12):3531-40. PubMed ID: 27013681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.
    Filion KB; Azoulay L; Platt RW; Dahl M; Dormuth CR; Clemens KK; Hu N; Paterson JM; Targownik L; Turin TC; Udell JA; Ernst P;
    N Engl J Med; 2016 Mar; 374(12):1145-54. PubMed ID: 27007958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
    N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Marso SP; Daniels GH; Brown-Frandsen K; Kristensen P; Mann JF; Nauck MA; Nissen SE; Pocock S; Poulter NR; Ravn LS; Steinberg WM; Stockner M; Zinman B; Bergenstal RM; Buse JB; ;
    N Engl J Med; 2016 Jul; 375(4):311-22. PubMed ID: 27295427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).
    Aroda VR; Bailey TS; Cariou B; Kumar S; Leiter LA; Raskin P; Zacho J; Andersen TH; Philis-Tsimikas A
    Diabetes Obes Metab; 2016 Jul; 18(7):663-70. PubMed ID: 26990378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.
    Wang T; Wang F; Zhou J; Tang H; Giovenale S
    Diabetes Metab Res Rev; 2016 Nov; 32(8):843-857. PubMed ID: 27037787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes.
    El Bekay R; Coín-Aragüez L; Fernández-García D; Oliva-Olivera W; Bernal-López R; Clemente-Postigo M; Delgado-Lista J; Diaz-Ruiz A; Guzman-Ruiz R; Vázquez-Martínez R; Lhamyani S; Roca-Rodríguez MM; Veledo SF; Vendrell J; Malagón MM; Tinahones FJ
    Br J Pharmacol; 2016 Jun; 173(11):1820-34. PubMed ID: 26993859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 and vitamin D: anti-inflammatory response in diabetic kidney disease in db/db mice and in cultured endothelial cells.
    Einbinder Y; Ohana M; Benchetrit S; Zehavi T; Nacasch N; Bernheim J; Zitman-Gal T
    Diabetes Metab Res Rev; 2016 Nov; 32(8):805-815. PubMed ID: 26991522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Liraglutide on Corneal Kindling Epilepsy Induced Depression and Cognitive Impairment in Mice.
    Koshal P; Kumar P
    Neurochem Res; 2016 Jul; 41(7):1741-50. PubMed ID: 27017512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?
    Strain WD; Smith C
    Diabetes Ther; 2016 Jun; 7(2):175-85. PubMed ID: 27010644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
    Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin hormone receptors are required for normal beta cell development and function in female mice.
    Omar B; Ahlkvist L; Yamada Y; Seino Y; Ahrén B
    Peptides; 2016 May; 79():58-65. PubMed ID: 27020250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-β peptide-induced impairment of spatial learning and memory in rats.
    Jia XT; Ye-Tian ; Yuan-Li ; Zhang GJ; Liu ZQ; Di ZL; Ying XP; Fang Y; Song EF; Qi JS; Pan YF
    Physiol Behav; 2016 May; 159():72-9. PubMed ID: 26992957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness.
    Ahuja V; Chou CH
    Curr Diab Rep; 2016 Jun; 16(6):47. PubMed ID: 27076180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The complexity of signalling mediated by the glucagon-like peptide-1 receptor.
    Fletcher MM; Halls ML; Christopoulos A; Sexton PM; Wootten D
    Biochem Soc Trans; 2016 Apr; 44(2):582-8. PubMed ID: 27068973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.